Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes
Amycretin led to a 1.8 reduction in HbA1c levels in the Phase II type 2 diabetes trial.
26 November 2025
26 November 2025
Amycretin led to a 1.8 reduction in HbA1c levels in the Phase II type 2 diabetes trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.